+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Next Generation RNA Therapeutics Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players- Product Image
Next Generation RNA Therapeutics Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players- Product Image
New

Next Generation RNA Therapeutics Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players

  • PDF Icon

    Report

  • 169 Pages
  • December 2025
  • Region: Global
  • Roots Analysis
  • ID: 6215965
Description Jump to:
The global next generation RNA therapeutics is estimated reach USD 940 million by 2035, at a CAGR of 68% during the forecast period.

NEXT-GENERATION RNA THERAPEUTICS MARKET: GROWTH AND TRENDS

Due to its critical role in protein production and gene function regulation in the human body, RNA is being explored as a possible therapeutic option. Researchers are recognizing the immense possibilities linked to RNA-based therapies, as they can precisely target and address conditions that were previously considered incurable. Nonetheless, the extremely volatile characteristics of these molecules pose considerable challenges to their use as therapeutic alternatives. In recent years, the emergence of advanced technologies and platforms has enhanced the interest of industry stakeholders in improved and altered RNA-based therapies, which are thought to be very stable and offer prolonged effects at relatively low doses. This category of modified RNA-based treatments is referred to as next generation therapies. The growing pipeline of RNA-based treatment modalities and favourable clinical trial results have encouraged several big pharma players to undertake initiatives for the development and advancement of these RNA therapeutics / vaccines.

Owing to the research and development efforts, substantial investment activity and increased participation of prominent players, the RNA therapeutics and vaccines market is anticipated to witness significant growth in the foreseen future.

NEXT-GENERATION RNA THERAPEUTICS MARKET: KEY INSIGHTS

The report delves into the current state of the next generation RNA therapeutics market identifies potential growth opportunities within the industry. Some key findings from the report include:

  • More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications.
  • 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio.
  • Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines.
  • Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell.
  • Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations.
  • Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field.

  • Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases.
  • Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 billion across various funding rounds in the past four years.
  • The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years.

  • The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of 68% between 2028 to 2035.

NEXT GENERATION RNA THERAPEUTICS MARKET

Vaccines Account for the Highest Share of the Next Generation RNA Therapeutics Market

Based on the type of modality, the market is segmented into RNA therapeutics and RNA vaccines. At present, RNA vaccines capture a substantial proportion of the next generation RNA therapeutics market. This trend is unlikely to change in the near future.

Replicating RNA Dominates the Next Generation RNA Therapeutics Market During the Forecast Period

Based on the type of molecule, the market is segmented into replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA. At present, replicating RNA holds the maximum share of the next generation RNA therapeutics market. However, self amplifying RNA is likely to drive the market in the near future.

Infectious Diseases Segment Captures the Highest Share of the Next Generation RNA Therapeutics Market

Based on the therapeutic area, the market is segmented into infectious diseases and oncological disorders. Currently, infectious diseases account for the 100% share of the next generation RNA therapeutics market. However, oncological disorders segment is likely to drive the market in the near future.

Intradermal Route Occupies for the Largest Share of the Next Generation RNA Therapeutics Market

Based on the route of administration, the market is segmented into intradermal, intramuscular and intravenous. Currently, intradermal route holds the majority share of the next generation RNA therapeutics market. However, intramuscular route is likely to drive the market in the near future.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Asia-Pacific. The majority of the share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in North America is expected to grow at a higher CAGR.

Example Players in the Next Generation RNA Therapeutics Market

  • Alphavax
  • Arcturus Therapeutics
  • Atyr Pharma
  • Gritstone Bio
  • HDT Bio
  • MiNA Therapeutics
  • VLP Therapeutics

NEXT GENERATION RNA THERAPEUTICS MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation RNA therapeutics market, focusing on key market segments, including [A] type of modality, [B] type of molecule, [C] therapeutic areas, [D] route of administration [E] and [F] key geographical regions.
  • Market Landscape: A comprehensive evaluation of next generation RNA therapeutics that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of modality, [B] type of molecule, [C] type of delivery vehicle, [D] phase of development [E] therapeutic area and [F] key niche market segments (circRNA and saRNA). Additionally, the chapter includes analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players (in terms of number of therapies).
  • Technology Landscape: A comprehensive evaluation of technologies that are being developed / deployed to support the development of next generation RNA therapeutics, considering various parameters, such as [A] class of molecule, [B] type of molecule, [C] capabilities of the technology, [D] therapeutic area and [E] highest phase of development. Additionally, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their [F] year of establishment, [G] company size, [H] location of headquarters and [I] operational model.
  • Drug Profiles: In-depth profiles of drug candidates that are in advanced stages of development, focusing on [A] details on its developer, [B] drug overview, [C] clinical trial information, [D] clinical trial endpoints, [E] clinical trial results and [F] estimated sales.
  • Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various next generation RNA therapeutics, based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] type of sponsor, [F] therapeutic area, [G] study design, [H] leading organizations (in terms of number of trials), [I] focus area and [J] geography.
  • Patent Analysis: Detailed analysis of various patents filed / granted related to next generation RNA therapeutics based on [A] type of patent (granted patents, patent applications and others), [B] patent publication year, [C] patent jurisdiction, [D] CPC symbols, [E] emerging focus areas, [F] patent age, [G] leading industry / non-industry players (in terms of number of patents filed / granted) and [H] patent valuation.
  • Partnerships and Collaborations: An analysis of partnerships established in this sector based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] focus of partnership, [E] purpose of partnership, [F] therapeutic area, [G] most active players (in terms of number of partnerships) and [H] the regional distribution of partnership activity in this market.
  • Funding and Investment Analysis: A detailed evaluation of the investments made in this domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] type of molecule, [D] amount invested, [E] geography, [F] purpose of funding, [G] stage of development, [H] therapeutic area, [I] most active players (in terms of number and amount of funding instances) and [J] leading investors (in terms of number of funding instances).
  • Big Pharma Analysis: A comprehensive examination of various initiatives focused on next generation RNA therapeutics undertaken by major pharmaceutical companies based on several relevant parameters, such as [A] number of initiatives, [B] year of initiative, [C] type of initiative, [D] purpose of initiative, [E] focus of initiative and [F] location of headquarters.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with the Research Team
  • Free Update if the Report is 6+ Months Old

Table of Contents

1. PREFACE
1.1. Next Generation RNA Therapeutics Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities
6. MARKET LANDSCAPE
6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies
7. TECHNOLOGY LANDSCAPE
7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model
8. DRUG PROFILES
8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.2.1. Developer Overview
8.2.2. Drug Overview
8.2.3. Clinical Trial Information
8.2.4. Clinical Trial Endpoints
8.2.5. Clinical Trial Results
8.2.6. Estimated Sales
8.3. ARCT-154
8.3.1. Developer Overview
8.3.2. Drug Overview
8.3.3. Clinical Trial Information
8.3.4. Clinical Trial Endpoints
8.3.5. Clinical Trial Results
8.3.6. Estimated Sales
8.4. GRT-C901
8.4.1. Developer Overview
8.4.2. Drug Overview
8.4.3. Clinical Trial Information
8.4.4. Clinical Trial Endpoints
8.4.5. Clinical Trial Results
8.4.6. Estimated Sales
8.5. VLPCOV-01
8.5.1. Developer Overview
8.5.2. Drug Overview
8.5.3. Estimated Sales
8.6. AVX901
8.6.1. Developer Overview
8.6.2. Drug Overview
8.6.3. Clinical Trial Information
8.6.4. Clinical Trial Endpoints
8.6.5. Clinical Trial Results
8.6.6. Estimated Sales
8.7. MTL-CEBPA + Sorafenib
8.7.1. Developer Overview
8.7.2. Drug Overview
8.7.3. Clinical Trial Information
8.7.4. Clinical Trial Endpoints
8.7.5. Clinical Trial Results
8.7.6. Estimated Sales
8.8. SLATE
8.8.1. Developer Overview
8.8.2. Drug Overview
8.8.3. Clinical Trial Information
8.8.4. Clinical Trial Endpoints
8.8.5. Clinical Trial Results
8.8.6. Estimated Sales
9. CLINICAL TRIAL ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography
10. PATENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances
13. BIG PHARMA INITIATIVES
13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players
14. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET
14.1. Key Assumptions and Methodology
14.2. Overall Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard
15. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET, BY TYPE OF MODALITY
15.1. Therapeutics: Forecasted Estimates (till 2035)
15.2. Vaccines: Forecasted Estimates (till 2035)
15.3. Data Triangulation and Validation
16. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET, BY TYPE OF MOLECULE
16.1. repRNA: Forecasted Estimates (till 2035)
16.2. saRNA: Forecasted Estimates (till 2035)
16.3. sacRNA: Forecasted Estimates (till 2035)
16.4. sa-mRNA: Forecasted Estimates (till 2035)
16.5. tRNA: Forecasted Estimates (till 2035)
16.6. Data Triangulation and Validation
17. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET, BY THERAPEUTIC AREA
17.1. Infectious Diseases: Forecasted Estimates (till 2035)
17.2. Oncological Disorders: Forecasted Estimates (till 2035)
17.3. Pulmonary Disorders: Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (till 2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (till 2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. OVERALL NEXT GENERATION RNA THERAPEUTICS MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. North America: Forecasted Estimates (till 2035)
19.1.1. US: Forecasted Estimates (till 2035)
19.2. Europe: Forecasted Estimates (till 2035)
19.2.1. France: Forecasted Estimates (till 2035)
19.2.2. Italy: Forecasted Estimates (till 2035)
19.2.3. Spain: Forecasted Estimates (till 2035)
19.2.4. UK: Forecasted Estimates (till 2035)
19.2.5. The Netherlands: Forecasted Estimates (till 2035)
19.3. Asia-Pacific: Forecasted Estimates (till 2035)
19.3.1. India: Forecasted Estimates (till 2035)
19.3.2. Japan: Forecasted Estimates (till 2035)
19.3.3. Singapore: Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation
20. OVERALL RNA THERAPEUTICS MARKET BY LEADING PLAYERS
20.1. Company A
20.2. Company B
20.3. Company C
20.4. Company D
20.5. Company E
21. CONCLUSION22. APPENDIX 1: TABULATED DATA23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List of Figures
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Overall Technology Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Partnerships and Collaborations
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Big Pharma Initiatives
Figure 4.8 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
Figure 5.2 Key Aspects of Next Generation RNA Molecules
Figure 5.3 Key Challenges Associated with Traditional RNA Modalities
Figure 5.4 Advantages of Using Next Generation RNA Modalities
Figure 6.1 Next Generation RNA Therapies: Distribution by Type of Modality
Figure 6.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Figure 6.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Figure 6.4 Next Generation RNA Therapies: Distribution by Phase of Development
Figure 6.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Figure 6.6 Most Active Players: Distribution by Number of Therapies
Figure 6.7 Clinical Stage Therapies: Distribution by Phase of Development
Figure 6.8 Clinical Stage Therapies: Distribution by Route of Administration
Figure 6.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Figure 6.10 Therapy Developer Landscape: Distribution by Year of Establishment
Figure 6.11 Therapy Developer Landscape: Distribution by Company Size
Figure 6.12 Therapy Developer Landscape:Distribution by Location of Headquarters
Figure 6.13 circRNA Therapies: Distribution by Phase of Development
Figure 6.14 circRNA Therapies: Distribution by Therapeutic Area
Figure 6.15 Most Active Players: Distribution by Number of circRNA Therapies
Figure 6.16 saRNA Therapies: Distribution by Phase of Development
Figure 6.17 saRNA Therapies: Distribution by Therapeutic Area
Figure 6.18 Most Active Players: Distribution by Number of saRNA Therapies
Figure 7.1 Next Generation RNA Technologies: Distribution by Class of Molecule
Figure 7.2 Next Generation RNA Technologies: Distribution by Type of Molecule
Figure 7.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Figure 7.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
Figure 7.5 Next Generation RNA Technologies: Distribution by Highest Phase of Development
Figure 7.6 Technology Developer Landscape: Distribution by Year of Establishment
Figure 7.7 Technology Developer Landscape: Distribution by Company Size
Figure 7.8 Technology Developer Landscape: Distribution by Location of Headquarters
Figure 7.9 Technology Developer Landscape: Distribution by Operational Model
Figure 8.1 Gemcovac®: Estimated Sales
Figure 8.2 ATYR1923: Estimated Sales
Figure 8.3 ARCT-154: Estimated Sales
Figure 8.4 GRT-C901: Estimated Sales
Figure 8.5 VLPCOV-01: Estimated Sales
Figure 8.6 AVX901: Estimated Sales
Figure 8.7 MTL-CEBPA + Sorafenib: Estimated Sales
Figure 8.8 SLATE: Estimated Sales
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2019
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Patients Enrolled
Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 9.7 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
Figure 9.9 Leading Organizations: Distribution by Number of Trials
Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 9.11 Clinical Trial Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Year-wise Trend, since 2019
Figure 10.3 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.4 Patent Jurisdiction: North American Scenario
Figure 10.5 Patent Jurisdiction: European Scenario
Figure 10.6 Patent Jurisdiction: Aisa-Pacific Scenario
Figure 10.7 Patent Analysis: Distribution by Patent Age
Figure 10.8 Patent Analysis: Distribution by CPC Symbols
Figure 10.9 Word Cloud Analysis: Emerging Focus Areas
Figure 10.10 Leading Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.12 Patent Analysis: Distribution by Patent Characteristics
Figure 10.13 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2019
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2019
Figure 11.4 Partnerships and Collaborations: Distribution by Year and Type of Molecule, since 2019
Figure 11.5 Partnerships and Collaborations: Distribution by Focus of Partnership
Figure 11.6 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Local and International Deals
Figure 11.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2019
Figure 12.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Molecule
Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested by Year, since 2019 (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.6 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million
Figure 12.7 Funding and Investment Analysis: Distribution by Year and Type of Funding, since 2019
Figure 12.8 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 12.9 Funding and Investment Analysis: Distribution by Stage of Development
Figure 12.10 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 12.11 Most Active Players: Distribution by Number of Funding Instances
Figure 12.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 12.13 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 13.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Figure 13.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 13.4 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
Figure 13.5 Big Pharma Initiatives: Cumulative Year-wise Trend, since 2019
Figure 13.6 Big Pharma Initiatives: Distribution by Focus of Initiative
Figure 13.7 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
Figure 14.1 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035), Base Scenario (USD Million)
Figure 14.2 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Figure 14.3 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Million)
Figure 15.1 Global Next Generation RNA Therapeutics Market: Distribution by Type of Modality (USD Million)
Figure 15.2 Global RNA Therapeutics Market, Forecasted Estimates (till 2035) (USD Million)
Figure 15.3 Global RNA Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 16.1 Global Next Generation RNA Therapeutics Market: Distribution by Type of Molecule (USD Million)
Figure 16.2 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 16.3 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 16.4 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 16.5 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 16.6 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (till 2035) (USD Million)
Figure 17.1 Global Next Generation RNA Therapeutics Market: Distribution by Therapeutic Area (USD Million)
Figure 17.2 Global Next Generation RNA Therapeutics Market for Infectious Diseases, Forecasted Estimates (till 2035) (USD Million)
Figure 17.3 Global Next Generation RNA Therapeutics Market for Oncological Disorders, Forecasted Estimates (till 2035) (USD Million)
Figure 17.4 Global Next Generation RNA Therapeutics Market for Pulmonary Disorders, Forecasted Estimates (till 2035) (USD Million)
Figure 18.1 Global Next Generation RNA Therapeutics Market: Distribution by Route of Administration, (USD Million)
Figure 18.2 Global Next Generation RNA Therapeutics Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Global Next Generation RNA Therapeutics Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (till 2035) (USD Million)
Figure 18.4 Global Next Generation RNA Therapeutics Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 Global Next Generation RNA Therapeutics Market: Distribution by Key Geographical Regions (USD Million)
Figure 19.2 Next Generation RNA Therapeutics Market in North America, Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Next Generation RNA Therapeutics Market in the US, Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Next Generation RNA Therapeutics Market in Europe, Forecasted Estimates (till 2035) (USD Million)
Figure 19.5 Next Generation RNA Therapeutics Market in France, Forecasted Estimates (till 2035) (USD Million)
Figure 19.6 Next Generation RNA Therapeutics Market in Italy, Forecasted Estimates (till 2035) (USD Million)
Figure 19.7 Next Generation RNA Therapeutics Market in Spain, Forecasted Estimates (till 2035) (USD Million)
Figure 19.8 Next Generation RNA Therapeutics Market in the UK, Forecasted Estimates (till 2035) (USD Million)
Figure 19.9 Next Generation RNA Therapeutics Market in the Netherlands, Forecasted Estimates (till 2035) (USD Million)
Figure 19.10 Next Generation RNA Therapeutics Market in Asia-Pacific, Forecasted Estimates (till 2035) (USD Million)
Figure 19.11 Next Generation RNA Therapeutics Market in India, Forecasted Estimates (till 2035) (USD Million)
Figure 19.12 Next Generation RNA Therapeutics Market in Japan, Forecasted Estimates (till 2035) (USD Million)
Figure 19.13 Next Generation RNA Therapeutics Market in Singapore, Forecasted Estimates (till 2035) (USD Million)
Figure 20.1 Next Generation RNA Therapeutics Market: Distribution by Leading Players, (USD Million)\

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4SR Biosciences
  • 8VC
  • Alexandria Real Estate Equities
  • Alltrna
  • AlphaVax
  • aMoon
  • Apple Tree Partners
  • Arcturus Therapeutics
  • Aspire Capital
  • AstraZeneca
  • Atlas Special Opportunities
  • aTyr Pharma
  • Aurora Vaccines
  • Avidity Partners
  • AyurMaya Capital Management Fund
  • BeiGene
  • MPM BioImpact
  • BioNTech
  • Camford Capital
  • Catalent
  • Charles River
  • Chimerna Therapeutics
  • Chimeron Bio
  • Circio
  • Circularis
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Colt Ventures
  • Cowen Healthcare Investments
  • Creative Biolabs
  • CSL Behring
  • CSL Seqirus
  • CureVac
  • Curia
  • Dualsystems Biotech
  • Duke-NUS Medical School
  • EcoR1 Capital
  • Eli Lilly
  • Elixirgen Therapeutics
  • Epidarex
  • Esperovax
  • F2 Ventures
  • Flagship Pioneering
  • FPV Ventures
  • Frazier Life Sciences
  • Friends of FSH Research
  • FUJIFILM
  • FUJIFILM Diosynth Biotechnologies
  • Genevant Sciences
  • George Mason University
  • Gilead Sciences
  • Ginkgo Bioworks
  • GlaxoSmithKline
  • Gritstone bio
  • hC Bioscience
  • HDT Bio
  • Hercules Capital
  • ImmunityBio
  • Imperial College London
  • Israeli Ministry of Health
  • Japanese Ministry of Economy, Trade and Industry (METI)
  • K2 HealthVentures
  • Konishiyasu
  • KYORIN Pharmaceutical
  • Laronde
  • Leaps by Bayer
  • Levatio Therapeutics
  • Maryland Industrial Partnerships
  • thisMerck
  • Michigan Rise
  • MiNA Therapeutics
  • miRecule
  • Miyako Capital
  • MPM Capital
  • MSA Capital
  • MUFG Bank
  • National Cancer Institute (NCI)
  • National Institutes of Health
  • Nobelpharma
  • Oncorus
  • OrbiMed
  • Orbital Therapeutics
  • Orna Therapeutics
  • Pan African Cancer Research Institute (PACRI)
  • Panacea Venture
  • Perceptive Advisors
  • Pfizer
  • Playground Global
  • Precision NanoSystems
  • Quanchuang Capital
  • Recipharm
  • ReCode Therapeutics
  • Redmile Group
  • Replicate Bioscience
  • Ring Code Biotech
  • Sanofi
  • Servier
  • ShapeTX
  • Silicon Valley Bank
  • Simnova
  • SK Impact Fund
  • Sojitz
  • Solve FSHD
  • Strand Therapeutics
  • SYTE.bio
  • Taiho Ventures
  • Takeda Ventures
  • Tevard Biosciences
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • National Institute of Allergy and Infectious Diseases
  • The National University Cancer Institute, Singapore (NCIS)
  • University of Nebraska Medical Center
  • The University of Texas Medical Branch (UTMB)
  • Therorna
  • Transine Therapeutics
  • TriLink BioTechnologies
  • University of Antwerp
  • UZ Gent
  • VaxEquity
  • Vertex Pharmaceuticals
  • Vida Ventures
  • Vingroup
  • VLP Therapeutics
  • Ziphius Vaccines
  • Zogenix (Acquired by UCB)
  • Zoic Capital

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

RNA Therapeutics Market and RNA Vaccines Market Industry Trends and Global Forecasts to 2035, by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players - Product Image

RNA Therapeutics Market and RNA Vaccines Market Industry Trends and Global Forecasts to 2035, by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players

  • Report
  • 170 Pages
  • Global
From
Investor Series: Opportunities in RNA Therapeutics Market - Product Image

Investor Series: Opportunities in RNA Therapeutics Market

  • Report
  • 174 Pages
  • Global
From
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 - Product Image

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024

  • Report
  • 351 Pages
  • Global
From
RNAi Drug Delivery: Technologies and Global Markets - Product Image

RNAi Drug Delivery: Technologies and Global Markets

  • Report
  • 141 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.